med PFS | HR (95% CI) | med OS | HR (95% CI) | |
---|---|---|---|---|
SE-Region | 5.2 (3.4–7.0) | – | 10.9 (7.8–14.0) | – |
MPACT (Gem/Nab-arm) | 5.5 (4.5–5.9) | – | 8.5 (7.9–9.5) | – |
Subgroup analysis | ||||
Tumour stage | ||||
Locally adv. | 6.8 (5.2–8.4) | 0.82 (0.48–1.40) p = 0.47 | 17.1 (7.6–26.6) | 0.62 (0.32–1.18) p = 0.14 |
Metastasised | 4.5 (3.3–5.7) | 9.4 (4.9–13.9) | ||
Metastatic burden | ||||
1–3 metastases | 5.5 (2.5–8.5) | 0.99 (0.53–1.86) p = 0.97 | 10.9 (5.5–16.3) | 0.63 (0.30–1.32) p = 0.22 |
> 3 metastases | 3.9 (2.4–5.4) | 6.9 (4.8–9.0) | ||
ECOG | ||||
0 | 6.2 (3.9–8.5) | 0.93 (0.56–1.54) p = 0.77 | 14.5 (7.5–21.5) | 0.73 (0.40–1.31) p = 0.29 |
1–2 | 4.5 (1.1–7.9) | 9.4 (6.3–12.5) | ||
Prior chemotherapy | ||||
Yes | 6.5 (2.9–10.1) | 0.82 (0.48–1.38) p = 0.45 | 13.2 (9.4–17.0) | 0.81 (0.44–1.46) p = 0.48 |
No | 5.1 (3.0–7.2) | 8.2 (5.3–11.1) | ||
Prior Surgery | ||||
Yes | 5.5 (2.1–8.9) | 0.89 (0.53–1.50) p = 0.67 | 12.0 (9.0–15.0) | 0.87 (0.48–1.58) p = 0.64 |
No | 5.1 (2.8–7.4) | 8.9 (5.3–12.5) |